Key result
LGE extent >14.4% on CMR predicts thromboembolic complications in HCM.
Why the study?
Thromboembolic complications are recognized in hypertrophic cardiomyopathy, but clinical and CMR predictors of these events required assessment.
Does the extent of late gadolinium enhancement predict thromboembolic events in patients with hypertrophic cardiomyopathy?
Observational
Does the extent of late gadolinium enhancement predict thromboembolic events in patients with hypertrophic cardiomyopathy?
Absolute Event Rate: 23% vs 8%
p-value: p=<0.0001
No takes yet. Share an insight, caveat, or question.
LGE extent may refine thromboembolic risk stratification in HCM; hypothesis-generating pending prospective validation.
Hohneck et al. (2020) conducted an observational in Hypertrophic cardiomyopathy. Late Gadolinium Enhancement (LGE) extent vs. No LGE or lower LGE extent was evaluated on LGE extent in patients with vs without thromboembolic events (p=<0.0001). Late gadolinium enhancement extent (>14.4%) on cardiovascular magnetic resonance independently predicts thromboembolic complications in patients with hypertrophic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: